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Abstract Intratumoral hypoxia has been associated with
poor prognosis in several solid tumors. The aim of this
study was to determine whether the hypoxia-associated
markers glucose transporter (GLUT)-1 and carbonic anhy-
drase (CA)-IX expression and preoperative hemoglobin
(Hb) levels correlate with presence of inguinofemoral or
distant metastases, and disease-free survival (DSS) in
vulvar squamous cell carcinoma (SCC) patients. Vulvar
SCC (n=103) were reviewed for histopathological charac-
teristics by an expert gynecopathologist and stained for
GLUT-1 and CA-IX. Clinical data and preoperative Hb
levels were obtained from medical records. No significant
correlations were observed between GLUT-1 or CA-IX
expression patterns and preoperative Hb levels, presence of
inguinofemoral or distant metastases and DSS. However,
anemic patients (Hb<11.2 g/dL) had significantly more
inguinofemoral metastases and lower Hb level was an
independent prognostic factor for a worse DSS (p<0.001).
The number of comorbidic conditions was inversely
correlated with preoperative Hb level. Preoperative Hb
levels are associated with poor DSS for vulvar SCC
patients, whereas tumor hypoxia reflected by GLUT-1 and
CA-IX expression does not have a predictive value.
Because preoperative Hb levels inversely correlated with
the number of comorbidic conditions and not with GLUT-1
or CA-IX expression, it is most likely that preoperative Hb
levels represent overall physical condition.
Keywords Vulvar squamous cell carcinoma.Prognosis.
Hypoxia.Anemia.Comorbidity
Introduction
Vulvar squamous cell carcinoma (SCC) accounts for 3–5%
of all gynecological malignancies. Positive inguinofemoral
lymph nodes have been found to be the most important
prognostic factor for vulvar SCC [1–3]. Currently, the
standard treatment for patients with early stage vulvar SCC
is wide local excision with uni- or bilateral inguinofemoral
lymphadenectomy via separate incisions that may lead to
impressive morbidity such as lymphedema. There are no
non-invasive diagnostic tests that are able to exclude
inguinofemoral lymph node metastasis with a high enough
certainty to safely omit a complete inguinofemoral lym-
phadenectomy [4]. Fortunately, the sentinel lymph node
procedure is an upcoming promising staging technique [5].
Limited research has been performed on immunohisto-
chemical markers to predict the presence of positive
inguinofemoral lymph nodes and the prognosis of the
individual patient with vulvar SCC. Fons et al. have
analyzed 16 immunohistochemical markers with potentially
prognostic value for patients with vulvar SCC. Lack of
caspase three expression, a key effector of cellular death,
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DOI 10.1007/s00428-010-0981-xwas associated with poor disease-specific survival (DSS) in
a multivariate analysis [6]. In addition, increased epidermal
growth factor receptor (EGFR) expression and increased
angiogenic response have been found to be associated with
decreased survival [7–11].
Hypoxia occurs in anemia [12], cancer, prolonged
exercise, and long-term ischemia with durations of several
hours or more [13]. Hypoxia may induce cell death,
although tumor cells may adapt to the hypoxic microenvi-
ronment by inducing a hypoxia-inducible factor (HIF)-1
mediated angiogenic response, and/or by altering their
metabolic activity [14]. The overall cellular consequences
of hypoxia are a decreased proliferation rate, increased
radio- and multidrug resistance, and increased invasive and
metastatic potential [15]. These adaptive responses promote
tumor progression and treatment resistance to both radio-
and chemotherapy. Several studies have shown that tumor
hypoxia is significantly related to poor patient prognosis in
various malignancies such as head and neck cancer, and
cervical cancer [16, 17].
Severalimmunohistochemicalmarkerscanassesshypoxia.
HIF-1 isconsidereda masterregulator ofthe cellularresponse
to hypoxia. However, although HIF-1 indicates tumor
aggressiveness, it is debatable whether it is also a reliable
marker of tumor hypoxia as HIF1 induction is also dependent
on other microenvironmental conditions [14]. Among others,
HIF-1 regulates the expression of the surface transmembrane
glucose transporters (GLUTs), especially GLUT-1 and
carbonic anhydrases (CAs) which are both involved in
energy metabolism [18–21]. Whereas GLUTs import glucose
across the cell membrane in an energy independent manner
to fuel anaerobic glycolysis [22], the subsequent intracellular
acidification is antagonized by CAs [23]. This results in an
acidic extracellular environment that may promote progres-
sion toward a more malignant phenotype [24]. Of all CAs,
CA-IX has the greatest magnitude of induction under
hypoxic conditions.
Oxygen delivery to tumors depends on tissue perfusion
and the oxygen-carrying capacity of the blood. It has been
suggested that a decrease in the oxygen-carrying capacity
of the blood caused by anemia may be a major causative
factor for the development of tissue hypoxia [25, 26]. In a
rat model, Kelleher et al. indeed demonstrated that tumor-
related anemia resulted in substantial worsening of tumor
oxygenation [27]. Both high CA-IX, GLUT-1 and low
preoperative hemoglobin (Hb) levels were found to be
associated with a poor DSS in different tumor types, e.g.,
cervical, ovarian, and head and neck carcinomas [28–36].
Studies that have analyzed the correlation between
hypoxia and prognosis in vulvar SCC are limited. In a
small-scale study (20 patients), only preoperative anemia
showed a correlation with nodal metastasis [37]. Therefore,
the aim of this study is to determine whether GLUT-1 and
CA-IX expression and preoperative hemoglobin levels
correlate with presence of inguinofemoral or distant
metastases and DSS in a large group of vulvar SCC
patients.
Materials and methods
From January 1st 1988 until December 31st 2005, 167
consecutive patients with vulvar SCCs were treated with a
curative intent in the Radboud University Nijmegen
Medical Centre. Only patients whose treatment consisted
of primary surgery were included. Tumors with a depth of
invasion of 1 mm or more in the operation specimen were
selected for this study. A total number of 103 paraffin-
embedded primary vulvar SCCs that met the above-
mentioned criterion with long-term follow-up were avail-
able for this study (last month of follow-up—August 2008).
All slides were reviewed for histopathological character-
istics by an expert gynecopathologist (JB). Clinical data
were obtained from medical records and comorbidity was
registered in accordance with the Comorbidity Index of
Mary E. Charlson [38].
All patients were staged according to the surgicopatho-
logical staging system for vulvar carcinoma of the
International Federation of Gynecology and Obstetrics
(FIGO). When a recurrence was diagnosed, the localization
of the recurrence was registered as local, skin bridge, groin,
pelvic, or distant. For analytical purposes, skin bridge
recurrences were considered to be groin recurrences and
pelvic recurrences considered to be distant recurrences.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections (4 μm)
were mounted onto Superfrost slides (Menzel-Gläser,
Braunschweig, Germany) and dried overnight at 37°C.
Tissues were dewaxed in xylene, rehydrated through graded
alcohols, and rinsed three times in phosphate-buffered
saline (PBS; pH 7.4) for 10 min. Following an antigen
retrieval step [sodium citrate (0.01 M; pH 6.0), 95°C,
10 min], tissue sections were preincubated with 20%
normal goat serum in PBS and subsequently incubated
overnight at 4°C with a polyclonal rabbit-anti-GLUT-1
(Dako, Glostrup, Denmark; 1:200) or rabbit-anti-CA-IX
(0.1 μg/mL, kindly provided by Dr. E. Oosterwijk, Dept. of
Experimental Urology, Radboud University Nijmegen
Medical Centre). Antibodies were diluted in PBS containing
1% bovine serum albumin (BSA). Slides were rinsed in PBS
for 10 min and incubated with biotinylated anti-rabbit IgG
(Vector, Burlingame, CA, USA) for 30 min at room
temperature (RT). A biotin–avidin peroxidase (CA-IX) or
alkaline phosphatase (GLUT-1) complex was generated
694 Virchows Arch (2010) 457:693–703according to standard procedures (Vector). Peroxidase was
visualized with 3-amino-9-ethylcarbazole (AEC, ScyTek,
Logan, UT, USA) and briefly counterstained with Mayer’s
hematoxylin. Alkaline phosphatase was visualized with Fast
Blue (20 mLTris–HCl pH 8.2, 4 mgNaphtol AS-MX,4.8 mg
Levamisole, and 20 mg Fast Blue BB salt) and counterstained
with Nuclear fast red (Vector). Slides were mounted with
Imsol (Klinipath, Duiven, The Netherlands) and subsequently
with Permount (Fisher Scientific, Fairlawn, NJ, USA).
Negative controls (buffer only) were included in each
analysis.
For GLUT-1/CD31 double staining, the sodium-citrate
antigen retrieval step and preincubation with normal
serum was followed by incubation with monoclonal
mouse-anti CD31 (Dako, clone JC70A, 1:20) overnight
at 4°C. After washing the slides with PBS for 10 min,
tissue sections were incubated with biotinylated anti-
mouse IgG (Vector), an avidin–peroxidase complex
(Vector) generated and visualized with AEC. Subsequently,
the GLUT-1 staining protocol (Fast Blue) was performed as
described above.
Evaluation of staining
Slides were scored (HvdN, LvK) blinded to clinicopatho-
logical data and results of other stainings. Because GLUT-1
and CA-IX function as transmembrane proteins, only
membranous staining was considered a positive result.
The percentage of positive cells and localization of staining
was determined and categorized in the following manner:
negative, less than 5% of tumor cells stained, between 5%
and 25%, between 25% and 75%, and over 75%. To avoid
small numbers, for GLUT-1 staining, the only tumor with
less than 5% cells stained was grouped together with 5–
25% and for CA-IX staining, tumors with over 75% tumor
cells stained (three tumors) were grouped together in a
category ≥25% tumor cells stained.
Hemoglobin levels
Preoperative hemoglobin levels were recorded from the
medical charts. All hemoglobin levels were taken within
1 week prior to surgery.
Statistical analysis
Data were entered in a computerized database and analyzed
using SPSS software (version 16.0.1 for Windows, SPSS).
Patient and tumor characteristics were compared using χ
2
and two-tailed Student’s t tests. Survival analysis was
performed by the Kaplan–Meier product limit method, and
survival rates were compared using log-rank statistics. Cox
regression analysis was used for confounder analysis. All
time-dependent outcomes were calculated from time of
pathological diagnosis. Patient data were censored when a
disease event had not occurred at the last follow-up. For the
endpoint “presence of inguinofemoral or distant metasta-
ses”, an event was defined as occurrence of inguinofemoral
metastases or metastasis in a distant organ. For DSS, only
deaths due to vulvar SCC were analyzed as events. Patients
who are still alive or died due to other causes than vulvar
SCC were censored at the date of last follow-up. Values of
p <0.05 were considered significant.
Results
Primary treatment and staging
A total number of 30 patients underwent a wide local
excision, 72 patients had a radical vulvectomy and for one
patient an exenterative procedure was performed. Postop-
erative radiotherapy was given to 31 patients (30%); no
patients were treated with adjuvant chemotherapy.
Median age of the patients was 72 years (range 31–
92 years). Nine (8.7%) patients had a FIGO stage I tumor,
43 (41.7%) patients a stage II, 32 (31.1%) patients a stage
III, and 19 patients (18.5%) a stage IV tumor.
Expression of GLUT-1 and CA-IX
To assess hypoxia in vulvar SCCs, we performed immuno-
histochemical analyses for the tissue hypoxia-associated
markers GLUT-1 and CA-IX. The median area stained by
GLUT-1 was 25% of the whole tumor. Often a diffuse
staining of a large tumor area was observed, with a focally
increased staining intensity (Fig. 1). Both cytoplasmic and
membranous GLUT-1 staining was observed, but only
membranous staining was considered positive staining. In
several cases, GLUT-1 expression was observed directly
adjacent to a blood vessel (Fig. 1e–f).
CA-IX staining was less pronounced than GLUT-1, with
a median staining area of only 1% (Fig. 2). CA-IX staining
was often observed at a distance from vessels.
Hemoglobin levels
With the aim to assess the role of anemia, preoperative
hemoglobin levels were recorded from medical charts.
Hemoglobin levels were available for 77 patients. Eight
patients (7.8%) had a Hb value below 11.2 g/dL and were
considered to be anemic. Eight patients had a Hb level
between 11.2 and 12.6 g/dL, and 15 patients had a Hb level
between 12.6 and 13.4 g/dL. Twenty patients had a Hb
level between 13.4 and 14.2 g/dL, and 26 patients had a Hb
level of 14.2 g/dL or higher.
Virchows Arch (2010) 457:693–703 695GLUT-1, CA-IX, and preoperative Hb levels in relation
to tumor characteristics
Tumor characteristics in relation to expression of GLUT-1
and CA-IX are summarized in Table 1. Less-differentiated
tumors demonstrated lower GLUT-1 expression levels.
There were no differences between tumor characteristics
with respect to GLUT-1 and CA-IX expression at the
invasive front of the tumors (data not shown).
Anemic patients (<11.2 g/dL) presented with tumors
with a larger diameter than patients with Hb levels within
the normal range (Table 2). Subsequently, the correlation
between GLUT-1 or CA-IX expression and Hb levels was
determined. GLUT-1 and CA-IX were inversely correlated
Fig. 1 GLUT-1 staining in vulvar squamous cell carcinomas.
Representative image of a negative staining (a), 40% (b), and 90%
positivity (c). High-power magnification (d) of indicated area in (c)
demonstrates clear membranous localization. Scale bars (a)–(c):
50 μm, (d): 10 μm. Membranous GLUT-1 staining of tumor cells
(blue) adjacent to erythrocyte-containing blood vessels (red) can be
observed (e and f). Erythrocytes are GLUT-1 positive and serve as an
internal control for positive staining. Microvessels, where diffusion
can occur, are indicated (arrows)
696 Virchows Arch (2010) 457:693–703(p=0.003, 95% CI −0.479 to −0.104). No correlation was
found between preoperative Hb levels and CA-IX or
GLUT-1 expression.
GLUT-1, CA-IX, and preoperative Hb levels in relation
to presence of inguinofemoral metastases
For GLUT-1 and CA-IX expression patterns, no differences
were found for presence of inguinofemoral or distant
metastases (Fig. 3a, b). An imbalance between oxygen
supply and consumption is more likely to occur in large
tumors (large diameter or great depth of invasion).
Therefore, we performed a subanalysis for large tumors
(diameter ≥38 mm or depth of invasion ≥8 mm, which are
both the mean values). Expression of GLUT-1 and CA-IX
did not differ between tumors smaller or greater than a
diameter of 38 mm or between tumors with a depth of
invasion smaller or greater than 8 mm. In addition, GLUT-1
and CA-IX expression were not associated with presence of
inguinofemoral or distant metastases in this subgroup of
large tumors (data not shown).
For preoperative Hb levels, significant differences were
found for presence of inguinofemoral metastases or distant
(log rank=0.001) when stratified as in Table 2, and log rank
<0.001 (Fig. 3c) when stratified between anemic patients
(Hb<11.2 g/dL) and patients with normal Hb levels
(>11.2 g/dL).
GLUT-1, CA-IX, and preoperative Hb levels
and disease-specific survival
Univariate Cox regression analysis showed that both GLUT-1
(HR 0.876, 95% CI 0.583–1.115) and CA-IX (HR 1.086, 95%
CI 0.794–1.477) were not predictive for DSS, whereas
preoperative Hb value was a prognostic factor (p<0.001,
HR=0.146, 95% CI 0.059–0.358). In addition, the number of
positive inguionofemoral lymph nodes and development of
groin or distant recurrence correlated with a poor DSS (p<
0.001). When these variables were included in a multivariate
Cox proportional hazards analysis, preoperative Hb level
turned out to be an independent prognostic factor for poor
DSS (p=0.021). These findings were confirmed in a linear
regression analysis, demonstrating that groin, pelvic, or
distant recurrences are independent of preoperative Hb level
(p=0.262). The Kaplan–Meier survival curves with
corresponding log-rank values for GLUT-1, CA-IX, and Hb
Fig. 2 CA-IX staining in vulvar squamous cell carcinomas. Repre-
sentative image of a negative staining (a), 10% (b), 60% (c), and 90%
positivity (d). High-power magnification of indicated area in (d)
demonstrates clear membranous localization. Scale bars (a)–(c):
50 μm, (d): 10 μm
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698 Virchows Arch (2010) 457:693–703level are shown in Fig. 4a–c. There was no difference in DSS
between tumors with and without GLUT-1 and CA-IX
expression at the invasive front (data not shown). This was
also found in a subanalysis for patients treated with adjuvant
radiotherapy (31 patients); preoperative Hb levels were
predictive for DSS (p=0.041), but not GLUT 1 and CAIX
expression in the tumor (log rank p=0.507 and 0.568,
respectively).
Comorbidity
The lack of a correlation between Hb levels and expression
of hypoxia-associated markers provided no evidence for a
link between anemia and tissue hypoxia. The correlation
between Hb levels and poor DSS has led us to analyze
whether Hb levels reflect the physical condition of the
patients. Twenty-eight patients had no comorbidic condi-
tions according to Charlson et al. [38], whereas one to six
comorbidic conditions were observed in 75 patients
(Table 3). The number of comorbidic conditions and Hb
value were inversely associated in a linear regression model
(p=0.020, 95% CI −0.295 to −0.026).
Discussion
Our study of 103 patients with vulvar SCC did not reveal a
prognostic value for the expression of the tissue hypoxia-
associated markers GLUT-1 and CA-IX. Although anemia
has been linked to tissue hypoxia [14], we did not find such
a correlation. However, low Hb values were associated with
multiple comorbidic factors and turned out to be an
independent prognostic factor for a poor DSS. Literature
about the relation between the expression of hypoxia-
associated markers and lymph node metastasis or survival
for vulvar SCCs patients is limited. A small-scale study
Table 2 Tumor characteristics of 77 vulvar SCCs in relation to preoperative Hb levels
Hb (g/dL)
<11.2 11.2–12.6 12.6–13.4 13.4–14.2 ≥14.2 p value
a
Local Number 8 8 15 20 26
Depth of invasion Median 9.5 10.5 9 9 7 NS
Range 2–25 8–15 1.7–27 2–18 1–15
Tumor diameter Median 51.5 35 38 29 28 0.05
Range 28–120 21–80 10–60 12–90 5–60
Differentiation grade Well 37.5% 12.5% 20% 25% 19.2% NS
Moderately 62.5% 37.5% 46.7% 60% 42.3%
Poor 50% 33.3% 15% 30.8%
Unknown 7.7%
Regional
Number of positive nodes Mean 1.87 1.63 0.73 1.10 1.15 NS
Range 0–30 –50 –30 –30 –8
Capsular breakthrough No 37.5% 37.5% 33.3% 25% 15.4% NS
Yes 50% 37.5% 6.7% 10% 26.9%
Not applicable 12.5% 25% 60% 65% 53.8%
Missing 3.8%
FIGO stage
I 20% 10% 7.7% NS
II 12.5% 25% 33.3% 50% 46.2%
III 50% 75% 33.3% 20% 30.8%
IV 37.5% 13.3% 20% 15.4%
Recurrence
No recurrence 25% 87.5% 66.7% 75% 61.5% NS
Local 25% 12.5% 20% 5% 23.1%
Groin 25% 13.3% 15% 3.8%
Distant 25% 5% 11.5%
Hb hemoglobin, FIGO International Federation of Gynecology and Obstetrics, NS not significant
ap values are only given when significant; anemic patients were compared with non-anemic patients
Virchows Arch (2010) 457:693–703 699comprising 20 patients likewise failed to demonstrate a
significant correlation between various measures of tumor
oxygenation and nodal metastasis [37].
Patients’ anemia may contribute to the establishment of
intratumoral hypoxic conditions by reducing oxygen delivery
to tumor tissues. In our study, no correlation between Hb
levelsandhypoxia-associatedmarkerscouldbedemonstrated.
Similarly, no association between Hb levels in patients before
surgery and expression of hypoxia-associated markers was
observed in 45 head and neck cancer and 79 colorectal
adenocarcinomas [39, 40]. It is generally known that anemia
has a negative impact on survival for cancer and non-cancer
patients [41, 42]. However, previous research has focused on
its correlation with hypoxia, but not as a representative for
physical condition. We demonstrated an increased number of
comorbidic conditions in vulvar SCC patients with low Hb
values (<11.2 g/dL), which in turn correlates with very poor
prognosis (Fig. 4c). This is consistent with the study of Wu
et al. who also found that the cohort of patients with anemia
had the highest prevalences of several diseases [42], with
even minimal deviations from an optimal range being
associated with an increased risk of 30-day postoperative
mortality [42]. A deterioration of prognosis with Hb levels
below 11.2 g/dL was also observed for cervical cancer
patients treated with radiotherapy [43]. The differential
diagnosis of anemia is extensive with chronic illness as a
frequent cause. Cardiac and vascular conditions were most
often present in our study population and may both be causes
of the observed anemia in those patients. Because bleeding
from a vulvar tumor rarely occurs, this factor is not likely
to explain the low Hb levels in patients with large tumors.
Therefore, it is more likely that low preoperative Hb levels
represent an impaired physical condition than tumor
hypoxia.
In our study, increasing percentages of GLUT-1 and CA-
IX expression were not associated with differences in
primary tumor characteristics (Table 1), presence of
inguinofemoral or distant metastases (Fig. 3), and DSS
(Fig. 4). This may indicate that tumor hypoxia is not
relevant for vulvar cancer or that the markers are of
insufficient specificity. Tumor hypoxia can be induced by
an inadequate function of the tumor vasculature indepen-
dent of Hb levels. Furthermore, CA-IX and GLUT-1 do not
necessarily behave in a coherent fashion [44] as we also
observed in this study. The role of GLUT-1 as an
endogenous marker for tumor hypoxia was found to be
questionable [45]. Expression of GLUT-1 is induced by a
Fig. 3 Low preoperative Hb level correlates with increased risk of
inguinofemoral or distant metastases. Presence of inguinofemoral or
distant metastases curves for patients subdivided into different GLUT-
1 expression patterns (a), CA-IX patterns (b), and preoperative Hb
levels (c). Low preoperative Hb levels significantly correlate with
increased risk of inguinofemoral or distant metastases
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deprivation, oncogenic transformation, inhibition of oxida-
tive phosphorylation, and osmotic stress [45]. Although
GLUT expression has been demonstrated at a distance from
vessels and adjacent to necrosis, the relationship with
hypoxia has not been investigated [26]. Because we
detected GLUT-1 expression directly adjacent to
erythrocyte-containing blood vessel, we conclude that
GLUT-1 is not a genuine hypoxia marker in vulvar SCC.
In prostate cancer, GLUT-1 mRNA expression correlates
with loss of differentiation [46]. In contrast, we detected
high GLUT-1 protein expression (i.e., >75%) more fre-
quently in well-differentiated SCC than in moderate and
poorly differentiated tumors (Table 1, p=0.001). The
relevance for vulvar SCC biology is currently unknown.
However, this correlation is not observed in all other cases
in which GLUT-1 is expressed by less than 75% of the
tumor cells. It has to be noted, however, that our semi-
quantitative scoring of staining profiles is not as accurate as
quantitative PCR. Small changes mRNA expression may
have a prominent effect on tumor cell biology, but this
altered gene expression may not be detected at the protein
level in a semi-quantitative manner. CA-IX expression has
been studied in a number of tumor types supporting the
notion that CA-IX represents tumor aggressiveness. CA-IX
is strongly induced by hypoxia in a broad range of tumor
cells [47, 48] and considerable co-localization with pimo-
nidazole staining was observed [16, 48]. High expression of
CA-IX is associated with poor survival in breast cancer,
small cell lung cancer, head and neck and cervical tumors
Table 3 Overview of patients’ comorbidity
Patients 103
No comorbidic conditions 28
Myocardial 38
Vascular 54
Pulmonary 7
Neurological 6
Endocrine 26
Renal 1
Liver 1
Gastrointestinal 1
Cancer 11
Miscellaneous 7
The total number exceeds the total number of patients included (103)
as some patients had multiple comorbidic conditions
Fig. 4 Anemic vulvar SCC patients have a poor disease-free survival.
Disease-free survival curves for patients subdivided into different
GLUT-1 expression patterns (a), CA-IX patterns (b), and preoperative
Hb levels (c). Low preoperative Hb levels significantly correlate with
reduced DSS
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strated for renal clear cell and rectal carcinomas [49–51],
indicating that the prognostic or predictive value for CA-IX
expression depends on tumor type. Our study does not
indicate prognostic value of CA-IX expression for vulvar
SCC patients.
In conclusion, we found that high GLUT-1 and CA-IX
protein expression levels do not predict DSS for vulvar
SCC patients. Furthermore, their expression did not
correlate with preoperative Hb levels. However, preopera-
tive Hb levels could predict DSS independently of the
development of a groin or distant recurrence, and also
correlated with the number of comorbidic conditions. It is
most likely that preoperative Hb levels represent overall
physical condition more than it predicts tumor hypoxia.
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